Summary
Edwards Lifesciences Corporation (EW) filed an 8-K report on October 21, 2004, to disclose its financial results for the third quarter of 2004. The filing primarily consists of a press release (Exhibit 99.1) detailing the company's performance. While the full press release is incorporated by reference, specific sections (the first two paragraphs and pages 7-13) are deemed "filed" under the Securities Exchange Act, meaning they are subject to specific disclosure requirements. This report provides investors with timely information on the company's operational and financial standing as of the end of the third quarter. Investors should review the attached press release for details on revenue, profitability, and any forward-looking statements or significant operational updates that may impact the company's valuation and future prospects. The filing itself is procedural, indicating the public dissemination of material financial information.
Key Highlights
- 1Edwards Lifesciences filed an 8-K on October 21, 2004, reporting Q3 2004 financial results.
- 2The primary information is contained within a press release (Exhibit 99.1) dated October 21, 2004.
- 3Specific portions of the press release (first two paragraphs and pages 7-13) are considered 'filed' under the Exchange Act.
- 4This filing serves to formally announce the company's quarterly financial performance to the market.
- 5Investors should refer to the press release for detailed financial metrics and operational updates.
- 6The report indicates the company's adherence to disclosure requirements for significant financial events.